Moreover, identifying the cancer types and patient subgroups that would benefit most from CX3CR1-engineered CAR-T cells, developing reliable biomarkers, and optimizing combination strategies with IL-15 or immune checkpoint inhibitors remain key areas for future investigation. Here, CX3CR1 is linked to cancer.